Personal information

Websites & social links

LinkedIn

Countries

Germany

Activities

Collapse all

Employment (2)

Heinrich-Heine-Universität Düsseldorf: Dusseldorf, Nordrhein-Westfalen, DE

2019-01-01 to 2019-07-12 | Researcher Postdoc (Institute of Pharmaceutical and Medicinal Chemistry)
Employment
Source: Self-asserted source
Stefanie Hagenow

Heinrich-Heine-Universitat Düsseldorf: Dusseldorf, Nordrhein-Westfalen, DE

2014-04-01 to 2018-12-10 | PhD Student (Institute of Pharmaceutical and Medicinal Chemistry)
Employment
Source: Self-asserted source
Stefanie Hagenow

Education and qualifications (3)

Heinrich-Heine-Universität Düsseldorf: Dusseldorf, Nordrhein-Westfalen, DE

2014-04-01 to 2018-12-10 | Dr. rer. nat. (PhD) (Institute of Pharmaceutical and Medicinal Chemistry)
Education
Source: Self-asserted source
Stefanie Hagenow

Heinrich-Heine-Universitat Düsseldorf: Dusseldorf, Nordrhein-Westfalen, DE

2011-04 to 2014-01 | Master of Science (Institute of Toxicology)
Education
Source: Self-asserted source
Stefanie Hagenow

Georg-August-Universität Göttingen: Gottingen, Niedersachsen, DE

2008-10 to 2011-11 | Bachelor of Science (Chemistry)
Education
Source: Self-asserted source
Stefanie Hagenow

Funding (2)

Investigations of neurotransmitter‐catabolizing enzymes: Cultivation of high‐level expression systems and inhibitor characterization

2017-09 to 2017-09 | Grant
European Cooperation in Science and Technology (Brussels, BE)
Source: Self-asserted source
Stefanie Hagenow

MAO-A/MAO-B modulation by novel histamine H3 receptor ligands

2015-08 to 2015-09 | Grant
European Cooperation in Science and Technology (Brussels, BE)
Source: Self-asserted source
Stefanie Hagenow

Works (17)

Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson’s Disease

Journal of Medicinal Chemistry
2021-06-09 | Journal article
DOI: 10.1021/acs.jmedchem.0c00914
Source: Self-asserted source
Stefanie Hagenow

<p>Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs</p>

Drug Design, Development and Therapy
2020-01 | Journal article
DOI: 10.2147/DDDT.S236586
Contributors: Jens Hagenow; Stefanie Hagenow; Kathrin Grau; Mohammad Khanfar; Lena Hefke; Ewgenij Proschak; Holger Stark
Source: check_circle
Crossref

The Search for Histamine H4 Receptor Ligands with Anticancer Activity among Novel (Thio)urea Derivatives

ChemistrySelect
2019-09-30 | Journal article
DOI: 10.1002/slct.201902747
Contributors: Enrique Domínguez‐Álvarez; Dorota Łażewska; Zsanett Szabó; Stefanie Hagenow; David Reiner; Márió Gajdács; Gabriella Spengler; Holger Stark; Jadwiga Handzlik; Katarzyna Kieć‐Kononowicz
Source: check_circle
Crossref

Alkyl derivatives of 1,3,5-triazine as histamine H4 receptor ligands.

Bioorganic & medicinal chemistry
2019-02 | Journal article
DOI: 10.1016/j.bmc.2019.02.020
PMID: 30792106
Contributors: Łażewska D; Mogilski S; Hagenow S; Kuder K; Głuch-Lutwin M; Siwek A; Więcek M; Kaleta M; Seibel U; Buschauer A et al.
Source: Self-asserted source
Stefanie Hagenow via Europe PubMed Central

Optimization and preclinical evaluation of novel histamine H3receptor ligands: Acetyl and propionyl phenoxyalkyl piperazine derivatives.

Bioorganic & medicinal chemistry
2018-11 | Journal article
DOI: 10.1016/j.bmc.2018.11.010
PMID: 30448256
Contributors: Szczepańska K; Karcz T; Kotańska M; Siwek A; Kuder KJ; Latacz G; Mogilski S; Hagenow S; Lubelska A; Sobolewski M et al.
Source: Self-asserted source
Stefanie Hagenow via Europe PubMed Central

Selenazolyl-hydrazones as Novel Selective MAO Inhibitors With Antiproliferative and Antioxidant Activities: Experimental and In-silico Studies.

Frontiers in chemistry
2018-07 | Journal article
DOI: 10.3389/fchem.2018.00247
PMID: 30018949
PMC: PMC6037691
Contributors: Elshaflu H; Todorović TR; Nikolić M; Lolić A; Višnjevac A; Hagenow S; Padrón JM; García-Sosa AT; Djordjević IS; Grubišić S et al.
Source: Self-asserted source
Stefanie Hagenow via Europe PubMed Central

Design, synthesis, and biological evaluation of novel oxadiazole- and thiazole-based histamine H3R ligands.

Bioorganic & medicinal chemistry
2018-06 | Journal article
DOI: 10.1016/j.bmc.2018.06.028
PMID: 29960729
Contributors: Khanfar MA; Reiner D; Hagenow S; Stark H
Source: Self-asserted source
Stefanie Hagenow via Europe PubMed Central

Novel naphthyloxy derivatives – Potent histamine H3 receptor ligands. Synthesis and pharmacological evaluation

Bioorganic & Medicinal Chemistry
2018-05 | Journal article
DOI: 10.1016/j.bmc.2018.04.023
Contributors: Dorota Łażewska; Maria Kaleta; Stefanie Hagenow; Szczepan Mogilski; Gniewomir Latacz; Tadeusz Karcz; Annamaria Lubelska; Ewelina Honkisz; Jadwiga Handzlik; David Reiner et al.
Source: check_circle
Crossref

Synthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H3R ligands.

European journal of medicinal chemistry
2018-04 | Journal article
DOI: 10.1016/j.ejmech.2018.04.043
PMID: 29723785
Contributors: Szczepańska K; Karcz T; Mogilski S; Siwek A; Kuder KJ; Latacz G; Kubacka M; Hagenow S; Lubelska A; Olejarz A et al.
Source: Self-asserted source
Stefanie Hagenow via Europe PubMed Central

Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease.

European journal of medicinal chemistry
2018-02 | Journal article
DOI: 10.1016/j.ejmech.2018.02.015
PMID: 29477889
Contributors: Affini A; Hagenow S; Zivkovic A; Marco-Contelles J; Stark H
Source: Self-asserted source
Stefanie Hagenow via Europe PubMed Central

Multipotente Liganden mit kombinierter Cholinesterase‐ und Monoaminooxidase‐Inhibition sowie Histamin‐H3R‐Antagonismus bei neurodegenerativen Erkrankungen

Angewandte Chemie
2017-10-02 | Journal article
DOI: 10.1002/ange.201706072
Contributors: Óscar M. Bautista‐Aguilera; Stefanie Hagenow; Alejandra Palomino‐Antolin; Víctor Farré‐Alins; Lhassane Ismaili; Pierre‐Louis Joffrin; María L. Jimeno; Ondřej Soukup; Jana Janočková; Lena Kalinowsky et al.
Source: check_circle
Crossref

Multitarget‐Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H3R Antagonism for Neurodegenerative Diseases

Angewandte Chemie International Edition
2017-10-02 | Journal article
DOI: 10.1002/anie.201706072
Contributors: Óscar M. Bautista‐Aguilera; Stefanie Hagenow; Alejandra Palomino‐Antolin; Víctor Farré‐Alins; Lhassane Ismaili; Pierre‐Louis Joffrin; María L. Jimeno; Ondřej Soukup; Jana Janočková; Lena Kalinowsky et al.
Source: check_circle
Crossref

Systematic Data Mining Reveals Synergistic H3R/MCHR1 Ligands.

ACS medicinal chemistry letters
2017-05 | Journal article
DOI: 10.1021/acsmedchemlett.7b00118
PMID: 28626527
PMC: PMC5467185
Contributors: Schaller D; Hagenow S; Alpert G; Naß A; Schulz R; Bermudez M; Stark H; Wolber G
Source: Self-asserted source
Stefanie Hagenow via Europe PubMed Central

Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B.

2017-01 | Journal article
DOI: 10.1038/srep40541
PMID: 28084411
PMC: PMC5233962
Contributors: Hagenow S; Stasiak A; Ramsay RR; Stark H
Source: Self-asserted source
Stefanie Hagenow via Europe PubMed Central

Polypharmacology of dopamine receptor ligands.

2016-07 | Journal article
DOI: 10.1016/j.pneurobio.2016.03.011
PMID: 27234980
Contributors: Butini S; Nikolic K; Kassel S; Brückmann H; Filipic S; Agbaba D; Gemma S; Brogi S; Brindisi M; Campiani G et al.
Source: Self-asserted source
Stefanie Hagenow via Europe PubMed Central

Dopamine D3 receptor agonists as pharmacological tools.

2015-09 | Journal article
DOI: 10.1016/j.euroneuro.2014.11.005
PMID: 25498414
Contributors: Kassel S; Schwed JS; Stark H
Source: Self-asserted source
Stefanie Hagenow via Europe PubMed Central

Pleiotropic effects of spongean alkaloids on mechanisms of cell death, cell cycle progression and DNA damage response (DDR) of acute myeloid leukemia (AML) cells.

2015-05 | Journal article
DOI: 10.1016/j.canlet.2015.02.030
PMID: 25697484
Contributors: Stuhldreier F; Kassel S; Schumacher L; Wesselborg S; Proksch P; Fritz G
Source: Self-asserted source
Stefanie Hagenow via Europe PubMed Central
How many people are using ORCID?